Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seriously I own 9800 shares and trade the stock also.
I used the word perceived in regard to interest rates as most people that invest in NRZ do not understand the tax structure equation within NRZ`s earnings and payouts.
The sell on the news is almost always what a stock will do on a good earnings report..................
FYI here's as good read for you posted today.........GLTY
https://seekingalpha.com/article/4118403-new-residential-strong-q3-long-term
DrStockonomics
Your average sell on the news with a down market today.
It`ll be harder to maintain the stocks advance with raising or perceived raising interest rates too.
2017 will go down as one of the leanest years for M&A across the sector in many years. This level of deal volume has not been seen since 2013. However, given the replenishment needs of biotech/drug giants, their robust balance sheets and possibly positive tax policy changes, 2018 should be a banner year for deals in the sector. Later this week, we will discuss several small and mid-cap names that make logical acquisition candidates in the year ahead.
Virtus LifeSci Biotech Clinical Trials ETF BBC Performance:
http://portfolios.morningstar.com/fund/holdings?t=BBC
For most biotech investors we own and trade a few individual stocks that we think are promising and will make a decent return over time. So here is an alternative power play for those returns in you favorite stocks without taking on the high risk owning one or more names only. BBC has 76 Positions within the BioShares Biotechnology Clinical Trials ETF as of 10/27/2017.
https://www.virtus.com/products/bioshares-biotechnology-clinical-trials-etf#shareclass.619/period.quarterly
As we transition from Fall to Winter, natural gas, diesel and furnace oil inventories are at the lower end of the five year average with diesel sitting some 3.6 million barrels below that benchmark. According to the U.S. Energy Department’s EIA (Energy Information Administration), heating bills this season will rise 17% for furnace oil, while natural gas is expected to record a 12% hike. All of this assuming winter doesn’t get worse than expected, in which case the EIA’s projections may be a tad too conservative. If the diesel inventories are considerably lower than in previous years, the picture for natural gas isn’t much better as storage levels are at their second lowest end-of-season level since 2009.
Adding grist to the mill is the overall robust demand picture for gasoline which, as we saw in Wednesday’s weekly status report by the EIA, contributed to a 4.4 million barrel draw in stockpiles. When to consider that an increase in the use of diesel or distillates due to prolonged cold weather, a rise in the price of oil is almost inevitable, regardless of whether or not OPEC and other producing countries like Russia agree to an extension of crude output curbs. As a consequence, gasoline prices appear to be heading towards sustained higher prices, breaking the downward price trends we see during the late Fall and Winter seasons.
Double bottom in!!!!!!!!!!!!!!!!!!!
The always reliable Old Farmer’s Almanac is calling for a harsher “cold and snowy” winter in the Northeast with “wintry chill, wet and white” weather for the mid-Atlantic. The Great Lakes Region doesn’t fare much better with their 2018 outlook calling for a “cold but average snowfall season ahead” while the Gulf Coast gets a “chilly, wet and soggy” forecast. The unpredictability of a La Nina forming this season could also make things a lot colder.
So what does that mean for you? Well, unless you are fortunate enough to be in the Midwest or the west coast of the U.S., it looks like everywhere else should be bracing for a winter that promises to be more unpleasant than what we are accustomed to. As we transition from Fall to Winter, natural gas, diesel and furnace oil inventories are at the lower end of the five year average with diesel sitting some 3.6 million barrels below that benchmark. According to the U.S. Energy Department’s EIA (Energy Information Administration), heating bills this season will rise 17% for furnace oil, while natural gas is expected to record a 12% hike. All of this assuming winter doesn’t get worse than expected, in which case the EIA’s projections may be a tad too conservative. If the diesel inventories are considerably lower than in previous years, the picture for natural gas isn’t much better as storage levels are at their second lowest end-of-season level since 2009.
Adding grist to the mill is the overall robust demand picture for gasoline which, as we saw in Wednesday’s weekly status report by the EIA, contributed to a 4.4 million barrel draw in stockpiles. When to consider that an increase in the use of diesel or distillates due to prolonged cold weather, a rise in the price of oil is almost inevitable, regardless of whether or not OPEC and other producing countries like Russia agree to an extension of crude output curbs. As a consequence, gasoline prices appear to be heading towards sustained higher prices, breaking the downward price trends we see during the late Fall and Winter seasons.
For 2018, Old Man Winter looks set to force open our wallets to keep warm and at the pumps.
The hits just keep on coming and firing on all cylinders for TGTX..........
Good for you and your timing.
Nice see green in AMZA`s holdings for a change.
Click on equity prices:
http://portfolios.morningstar.com/fund/holdings?t=AMZA
I finally picked up some more today myself at $8.10 and $7.95. About hit my limit on this one as it will start getting into my trading capital if I have to keep averaging down from here. I didn`t get this Q`s dividend as I had bought too late. Looking forward to the juicy dividend next Q.........
Good points. Looking at the stock's daily trading one has to wonder how much shorting, like with most of the MLP`s stocks, is going on in $AMZA. Still looking for the next entry......
Bottom Fishing For A 20% Yield On Qualified Distributions
Oct. 22, 2017 9:15 AM ET
https://seekingalpha.com/article/4115274-bottom-fishing-20-percent-yield-qualified-distributions
I`m with you on the double bottom likelihood but not confident enough yet to pull the trigger and buy more as the stock has had consistent down days pretty much non stop and ETF`s holdings are selling down too.
Hope management is hedging accordly.....
Another thing the market is discounting:
TG Therapeutics, Inc. Recaps Clinical Data Presentations At The Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting Oct 16, 2017 7:30 AM EDT
B-cell depletion data and MRI data at 24 weeks (6 months) to be presented
Abstract data shows complete (100%) elimination of T1 Gd-enhancing lesions at week 24
Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer stated, "We are excited to release the first clinical MRI data of TG-1101 in patients with RMS as we believe the abstract data presents an extremely compelling case for the use of TG-1101 in the treatment of patients with MS. While still early, the data thus far is setting the stage for a best-in-class profile for TG-1101 in treating MS. We are looking forward to presenting the full data on the first three cohorts (n=24) through 24 weeks (6 months) of treatment at the ECTRIMS-ACTRIMS meeting next week." Mr. Weiss continued, "We will continue to update these data at multiple conferences over the next year as we treat and follow the full 48 patients (from the 6 cohorts) for up to 1 year. With our Phase 3 program now underway pursuant to a Special Protocol Assessment (SPA), we believe MS represents the next level of growth for the Company."
Also on Tuesday:
TG Therapeutics analyst commentary at Jefferies TG Therapeutics 16% selloff yesterday 'excessive,' says Jefferies. Jefferies analyst Matthew Andrews calls the 16% pullback yesterday in shares of TG Therapeutics "excessive" and recommends buying the dip. The FDA feedback that use of overall response rate to support accelerated approval is a review issue "seems obvious and not a major negative," Andrews tells investors in a research note. The agency working with TG to identify how to use the Genuine study's progression free survival to support full approval is positive, suggesting it sees ublituximab's benefit in chronic lymphocytic leukemia, the analyst adds. Andrews keeps a Buy rating on TG Therapeutics with a $23 price target.
TG Therapeutics analyst commentary at SunTrust TG Therapeutics selloff overdone, says SunTrust. SunTrust analyst Yatin Suneja said the selloff in Buy rated TG Therapeutics is a buying opportunity and would buy shares aggressively ahead of TG-1101's upcoming data presentation at ECTRMIS.
Raymond James sees exchange offers for Windstream debt as 'good strategic move' Raymond James analyst Frank Louthan IV notes that Windstream announced a series of exchange offers for several of its debt issuances out to 2023. The analyst believes this is a "good strategic move" to attempt to get the issue taken off the table, while getting the 2023 bonds in question potentially exchanged and the default issue resolved inside of the 60-day window established by Aurelius's letter to the trustees on September 21. Further, the strategy potentially clears some of the matter up ahead of the legal timeline that Louthan believes will stretch into 2018, but like all chess games, its likely part of the entire game, not the end. He reiterates an Outperform rating on the shares.
Looks as though we`ll need to wait through earnings to see the their holdings numbers as they have been selling off of late.
Top 10 Holdings As of 09/28/2017
Symbol Company Sector YTD Return as of 10/17/2017) % of Assets
ETP Energy Transfer Partners LP Energy -24.44% 15.77%
WPZ Williams Partners LP Energy +3.58% 10.81%
BPL Buckeye Partners LP Energy -18.33% 7.98%
ETE Energy Transfer Equity LP Energy -8.13% 7.54%
EPD Enterprise Products Partners LP Energy -3.37% 6.71%
MPLX MPLX LP Partnership Units Energy -0.09% 5.94%
EEP Enbridge Energy Partners LP Energy -39.56% 5.61%
ENLK EnLink Midstream Partners LP Energy -12.16% 4.75%
MPC Marathon Petroleum Corp Energy +12.23% 4.70%
ANDX Andeavor Logistics LP Energy -6.55% 4.55%
mrguitar
Unfortunately that is very true. The algorithmic system software that all the trading houses have now trade the news, chart divergences and 0.0001 tenth of a cent in a stock to make money. It really affects any stock within a millisecond to scalp no matter whether the news is good or bad.
If you really look at all the world markets as a whole they are really geared to the big corporate money centers.
The retail investors have no real concern from the SEC, so the way for us to make serious money is to game the system at its own game.
This is a manufactured sell off so you trade it accordingly based on the known fundamentals you know about $TGTX and the charts. GLTY
This should be of interest to all shareholders.
Uniti Group Inc. to Present at the Wells Fargo Securities 2017 Media & Telecom Conference
Mon October 16, 2017 4:15 PM|GlobeNewswire|About: UNIT
LITTLE ROCK, Ark., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Uniti Group Inc. (UNIT) (Nasdaq:UNIT) announced today that its President and Chief Executive Officer, Kenny Gunderman, and Executive Vice President, Chief Financial Officer and Treasurer, Mark A. Wallace, are scheduled to participate at the Wells Fargo Securities 2017 Media & Telecom Conference. The presentation is scheduled for 9:55 AM ET on November 7, 2017 in New York, NY.
You may access a live webcast of the event on Uniti’s website at www.uniti.com under the Investors tab. The webcast will be available for replay for a limited time on Uniti’s website following the presentation.
ABOUT UNITI
Uniti, an internally managed real estate investment trust, is engaged in the acquisition and construction of mission critical communications infrastructure, and is a leading provider of wireless infrastructure solutions for the communications industry. As of July 3, 2017, Uniti owns 4.8 million fiber strand miles, 631 wireless towers, and other communications real estate throughout the United States and Mexico. Additional information about Uniti can be found on its website at www.uniti.com.
INVESTOR AND MEDIA CONTACTS:
Mark A. Wallace, 501-850-0866
Executive Vice President, Chief Financial Officer & Treasurer
mark.wallace@uniti.com
Jim Volk, 501-850-0872
Vice President, Finance & Investor Relations
jim.volk@uniti.com
https://resource.globenewswire.com/Resource/Download/c14145ad-4e26-4052-98f7-486d336e2b7c?size=1
Source: Uniti Group Inc. 2017 GlobeNewswire, Inc.
Amazing we got another opportunity to pick up shares under $10.00.
Telecom and energy, both good specks going forward......
Agree thanks..........
Sure is discouraging when you have so many Phase 3 trials ongoing and you have this report come up on your trading system. Does not show a lot of confidence no matter why they sold this late in the game!
During the most recent quarter, 60K shares were sold in insider trading.
Was nice to be able to fill out my position today. Here's to looking forward to a profitable future..........
Exactly!!!!!!!!
Sooner rather than later the stock is going to trade up 40% on the day as the deep value is uncovered...............
Jumpinjackas
If you're posting to me with that question i'll be totally honest. I`ve done heavy research on this company and have traded it with a sell again today.
I can find no reason to have much faith in this management team as they have too many trials ongoing that are never ending. They use the markets as their personal ATM all the time and enrich themselves with cheap options.
They have had and open ended options to partner with a number of high profile companies and none have accepted.
This for me was an interesting play until you dig deeper. My last play on this ended today and if the company EVER brings something to market i'll be shocked yet happy for the people it helps. GLTY
BTW- They still have not yet tapped the U.S. depository account ATM they just filed for and I believe it was a very weak Australian offering they just tendered.
The writeups are becoming better informed and researched....
Uniti: Buy This 'Busted IPO' Yielding 15%?
https://seekingalpha.com/article/4112105-uniti-buy-busted-ipo-yielding-15-percent
Looks as though stock has made a bottom and is going to run up here. Need to break above $2.14 and hold to continue a new breakout. Taken a small position today in this value play and see about adding as the stock warrants....
This analysis was provided a week or so before the vultures started circling.
Uniti Group: Fair Value Of About $40 Based On Asset Value And AFFO
http://www.topstocksblog.com/uniti-group-fair-value-of-about-40-based-on-asset-value-and-affo.html
This play is going to be a great return on my purchase.
Wednesday, October 4, 2017 12:20 p.m. ET
Uniti Group at the Deutsche Bank 25th Annual Leveraged Finance Conference
http://investor.uniti.com/phoenix.zhtml?p=irol-eventDetails&c=253961&eventID=5263807
In for my share of this overly shorted misunderstood play.......
Looks like pricing between $9.35-$10.00
This is why the stock had a hard time breaking out further on all the upgrades and great PR`s the past few days.
Wait to buy again after the pricing....
Press Release: Array BioPharma Announces Proposed Public Offering of Common Stock
4:02 pm ET September 13, 2017 (Dow Jones) Print
Array BioPharma Announces Proposed Public Offering of Common Stock
PR Newswire
BOULDER, Colo., Sept. 13, 2017
BOULDER, Colo., Sept. 13, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock. Array BioPharma also intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Array BioPharma.
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the proposed offering. Piper Jaffray & Co. is also acting as a bookrunner for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The shares are being offered by Array BioPharma pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (SEC) and became effective. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC, and will be available on the SEC's website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, telephone: 866-803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, Attn: Prospectus Department, telephone: 631-274-2806; or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attn: Prospectus Department, telephone: 800-747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the proposed public offering. These statements involve significant risks and uncertainties, including those discussed in the preliminary prospectus supplement related to the offering and in our most recent annual report filed on Form 10-K. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. There can be no assurance that Array BioPharma will be able to complete the offering. We are providing this information as of September 13, 2017. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
CONTACT: Tricia Haugeto, Array BioPharma
(303) 386-1193
thaugeto@arraybiopharma.com
Array BioPharma Is Maintained at Overweight by Cantor Fitzgerald
9:33 am ET September 11, 2017 (Dow Jones) Dow Jones Newswires
September 11, 2017 09:33 ET (13:33 GMT)DJ Array BioPharma Price Target Raised to $15.00/Share From $13.00 by Cantor Fitzgerald(END) Dow Jones Newswires
Ratings actions from Benzinga: http://www.benzinga.com/stock/ARRY/ratings